About CSL
CSL is a publicly listed company based in Melbourne (Australia) founded in 1916. CSL is recognized as a global leader in biotechnology. It operates on a Direct-to-Consumer (D2C) and Professional Services model. CSL has completed 1 acquisition, including CSL Vifor. Its chief executive, as recorded, is Paul McKenzie. Its website csl.com draws about 173 thousand monthly visits. CSL offers products and services including CSL Behring Biotherapies, CSL Seqirus Vaccines, and CSL Vifor Therapies. Its focus areas include Biotechnology, Biotherapeutics, Pharmaceuticals and Vaccines. Its legal entity is CSL Limited.
Company details
CSL is established as a prominent biotechnology company with operations through CSL Behring, CSL Seqirus, and CSL Vifor. The company is focused on developing and delivering biotherapies for rare and serious diseases, vaccines for public health, and therapies for iron deficiency and nephrology. Solutions are provided across multiple sectors including healthcare and pharmaceuticals, with an emphasis on innovation and patient care. A global presence is maintained with headquarters in Melbourne, Australia, and additional key locations worldwide.
- Investments & Acquisitions
Products & Services of CSL
CSL offers a comprehensive portfolio of products and services, including CSL Behring Biotherapies, CSL Seqirus Vaccines, and CSL Vifor Therapies.
Biotherapies for rare and serious diseases are developed.
Influenza and other vaccines are produced globally.
Therapies for iron deficiency and nephrology are offered.
Apps and channels of CSL
its YouTube channel CSL has 1.72K subscribers and 30 videos.
Videos from CSL
The most watched videos on CSL's YouTube channel, CSL (1.72K subscribers). Click a video to play it here.
More on CSL.
People of CSL
425 people are tracked at CSL (207 in leadership, 8 in board & advisors, 210 in team).
| Name | Role | Group |
|---|---|---|
Paul McKenzie | CEO | Leadership |
Diego Sacristan | Head Of International; CSL Behring | Leadership |
Matt Tripp | Senior Financial Business Partner | Leadership |
Jordi Pont Arnaiz | Associate Director Sales & Marketing Commercial Spain | Leadership |
Farana Power | Executive Assistant To VP Of Commercial Operations - International Markets And Pandemic | Leadership |
Keely Beck Zipp | Vice President, Immunoglobulins TA & Global Commercial Development Portfolio Planning | Leadership |
Jessica Volk | Director, Strategy & Insight | Leadership |
Laura Schreder | Country & Site Communications Lead - EMEA | Head Of Site Communications Marburg | Leadership |
Dr. Michael Plater | Senior Director, Global Business Development & Licensing | Leadership |
Joel Hanson | Head Of Project Delivery, US | Leadership |
Chris Larkins | Senior Vice President Operations | Leadership |
Michael Bien | Senior Director Project Management | Leadership |
Elyse Muñoz | Associate Director, Market Intelligence | Leadership |
Leslie Bannon | Enterprise Head Of Alliances | Leadership |
Sue Thorn | Senior Manager, Communications Business Partner For R&d, Vaccines | Leadership |
Philippe Hebert | General Manager | Leadership |
Lukas Limbach | Director, Operations And International Demand Planning | Leadership |
Camilla Shen | Vice President Mid-size EMEA Markets | Leadership |
Kristina Harrison | Director, Pandemic Contracts North America | Leadership |
Fiona Mead | Company Secretary And Head Of Group Governance | Leadership |
405 more people are available in the full profile.
Complete people profiles for CSL
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CSL
CSL is a publicly listed company on the ASX with ticker symbol CSL in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Oct 2008
- Listed onOTCMKTS: CMXHF
- Listed entityCSL LIMITED
- Exchange sectorHealth technology
Investments & Acquisitions by CSL
CSL has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CSL Vifor.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Plasma-derived therapies and vaccines are provided for rare diseases. | viforpharma.com | Opfikon, Switzerland | 1872 | Dec 2021 | $11.7B |
Complete acquisition details for CSL
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of CSL
3 dated milestones of CSL across 105 years, from founding to its latest funding, stage changes and deals.
- Founded CSL is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires CSL Vifor.
Web traffic of CSL
The website of CSL (csl.com) receives about 172.8K visits a month.
- Monthly visits172.8K
▲ 29.6% vs previous month
Websites whose visitors overlap most with CSL. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
fool.com.au | fool.com.au | 100% | #28,469 | – | |
argonaut.com | argonaut.com | 81% | #3,201,548 | – | |
pccw-hkt.com | pccw-hkt.com | 73% | – | ||
| cochinshipyard.in | 69% | 266.6K | #285,612 | View details | |
| stockhead.com.au | 60% | 301.4K | #216,912 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for CSL
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Csl
Complete news archive for CSL
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CSL
CSL was founded in 1916.
CSL is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Paul McKenzie is the CEO of CSL, as recorded in our data.
CSL is established as a prominent biotechnology company with operations through CSL Behring, CSL Seqirus, and CSL Vifor. The company is focused on developing and delivering biotherapies for rare and serious diseases, vaccines for public health, and therapies for iron deficiency and nephrology. Solutions are provided across multiple sectors including healthcare and pharmaceuticals, with an emphasis on innovation and patient care. A global presence is maintained with headquarters in Melbourne, Australia, and additional key locations worldwide.
CSL offers CSL Behring Biotherapies, CSL Seqirus Vaccines, and CSL Vifor Therapies.
Yes, CSL is publicly traded on ASX under the ticker symbol CSL.
CSL has made 1 acquisition, including CSL Vifor.
CSL operates through Csl Limited.
The website of CSL receives about 173 thousand visits a month.